AR-V7 Predicts Poor Response to Enzalutamide and Abiraterone in Prostate Cancer
Sign in to PracticeUpdate
Only registered members have full access to PracticeUpdate content.
Additional Info
Disclosure statements are available on the authors' profiles:
AR-V7 Variant and Resistance to Enzalutamide and Abiraterone in Prostate Cancer
N. Engl. J. Med 2014 Sep 03;[EPub Ahead of Print], ES Antonarakis, C Lu, H Wang, B Luber, M Nakazawa, JC Roeser, Y Chen, TA Mohammad, Y Chen, HL Fedor, TL Lotan, Q Zheng, AM De Marzo, JT Isaacs, WB Isaacs, R Nadal, CJ Paller, SR Denmeade, MA Carducci, MA Eisenberger, J LuoFrom MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.